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ABSTRACT 
DNA Methylation acts as an essential regulatory mechanism of transcription affecting 
chromatin structure, which is established and maintained by the co-ordinate action of three 
DNA methyltransferases: DNMT1, DNMT3A and DNMT3B and histone modifications.  
Recent studies show that epigenetic change plays a major role in silencing a variety of 
methylated tissue-specific and imprints genes in many cancer types. Lymph node cancer is 
considered to result in part from the accumulation of multiple genetic alterations and leading 
to oncogene over expression and loss of function of tumor suppressor. The aim of this study 
was to check the expression of DNMT3A and DNMT3B in both normal and cancer cell. Both 
DNMT3A and DNMT3B shows over expression in cancer cell indicating their involvement 
in lymph node cancer. 
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   1. INTRODUCTION 
1.1 Epigenetics is the study of heritable changes in phenotype (appearance) or gene 
expression caused by mechanisms other than changes in the underlying DNA sequence. 
These changes may remain through cell divisions for the remainder of the cell's life and 
may also last for multiple generations. However, there is no change in the 
underlying DNA sequence of the organism. Epigenetics is beginning to form and take 
shape as a new scientific discipline, which will have profound impact on Medicine and 
essentially all fields of biology.  Epigenetics covers many different levels of biological 
control from variegated expression in Drosophila to chromatin structure and modification 
down to DNA methylation and relates to different biological systems. 
 
 
           
Figure1.Epigenetic modification (Image: UNSW Embryology Molecular 
Development – Epigenetics, Nature 441,143-145, 11 May, 2006).   
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   1.2  TERMS USED 
 
I. CpG Island - A region of vertebrate DNA about 0.5–2 kb in length that does not show 
the 80% suppression in the frequency of occurrence of this dinucleotide observed in bulk 
DNA. CpG islands are often associated with genes and are not methylated in the 
germline. 
 
II. De novo methylation -New methylation of previously unmethylated CpG sites.  During 
development it occurs, particularly on genes located on the inactive X chromosome in 
female mammals on imprinted genes and commonly occurs in cancer cells. 
 
III. DNA methyltransferase (DNMT) - Enzymes transfer the methyl group from S-
adenosyl-L-methionine (SAM) to the 5 position of cytosine shows a marked preference 
for CpG palindromes in double-stranded DNA in which one cytosine is already 
methylated. Three active mammalian enzymes have been identified are: DNMT-1, 3A, 
and 3B. 
 
IV. Hypermethylation A process of increased methylation of a region of DNA or an 
individual CpG site. 
 
V. Hypomethylation A process of decreased methylation of a region of DNA or an 
individual CpG site.       
 
VI. 5-Methylcytosine- Only modified base in vertebrate. DNA found almost exclusively at 
CpG sites and is formed by the enzymatic transfer of a methyl group from S-adenosyl-L-
methionine to the 5 position of the cytosine ring in newly synthesized DNA. 4% of 
cytosine is modified in this way, and 5-methylcytosine makes up 1% of the bases in 
human DNA.  
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         1.3 DNA METHYLATION  
 5-Methylcytosine is formed by the cytosine residues modification at the CpG 
dinucleotide sequence in double-stranded DNA in a reaction catalyzed by DNA 
methyltransferase enzymes. The three known enzymes (DNMT-1, DNMT-3a, and 
DNMT-3B) takes methyl group from S-adenosyl methionine to the 5position of the 
cytosine ring and this modification is the only naturally occurring covalent base change 
seen in vertebrate DNA. DNA methylation has been stimulated by observations that 
DNA methylation contributes to the silencing of genes on the inactive X chromosome, 
imprinted genes, and intragenomic parasites. DNA methylation is essential for vertebrate 
development. In addition to its role in suppressing the expression of genes by interfering 
with the function of promoters, DNA methylation helps in stability of repetitive DNA 
sequences and may also be involved in processes resulting in allelic loss. Changes in 
gene expression and losses of chromosomes are fundamental to the development of 
neoplasia and thus DNA methylation is likely to play an important part in generating the 
oncogenic phenotype.5-Methylcytosine is inherently mutagenic in both prokaryotes and 
eukaryotes and contributes to more than one-third of all of the point mutations that cause 
human genetic diseases. Thus the modified base, which constitutes only 1% of human 
DNA, is the site of more than 30% of all point mutations. An important discovery has 
been the observation that a significant number of inactivating point mutations in tumour 
suppressor genes, which are responsible for tumour initiation and progression, also occur 
at DNA methylation sites in somatic cells. DNA methylation therefore influences several 
key molecular events known to contribute to carcinogenesis (Peter, 2002). 
                   
    Figure 2. DNA methylation at cytosine residue Yim, G.,2004. 
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Inheritance of the DNA methylation pattern.  The DNA methyltransferase can methylate only 
the CG sequence paired with methylated CG.  The CG sequence not paired with methylated CG 
will not be methylated.  Hence, the original pattern can be maintained after DNA replication. 
       
               
        Figure 3. Inheritance of DNA methylation (http://www.webooks.com/MoBio/Free/Ch7F2.htm) 
 
                              
Figure 4. DNA Methylation in Vertebrates (Dr.Richard Mehaan: Chromosomes and Gene 
Expression).  
 
Meehan: C 
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& Gene Expression 
1.4 METHYLATION CHANGES IN TUMOR TISSUES 
Early studies on methylation changes in human tumors demonstrated a 
hypomethylation associated with the malignant state, and a generalized decrease in the 
amount of 5-methylcytosine per genome occurs in cancer cells. However, more detailed 
studies have shown that although hypomethylation of the genome occurs, the change in 
distribution of methyl groups within transformed cells is not random. Some areas of 
DNA, such as CpG islands, show hypermethylation, even though the total amount of 5-
methylcytosine per cell decreases. The mechanisms underlying these changes remain 
unknown; however, these data suggest that early changes in the DNA methylation 
machinery accompany and may directly participate in the process of transformation. The 
fact that changes in the methylation of CpG islands located in the promoters of growth 
regulatory genes can result in their permanent inactivation has led to the idea that 
abnormal hypermethylation should be considered one of the pathways resulting in tumor-
suppressor gene inactivation as outlined by Alfred Knudson.  
 
Knudson proposed that two hits were required for the full inactivation of a tumor 
suppressor gene and this has been shown to be correct in almost all cancers that have 
been examined for mutations and losses of heterozygosity. Most of the focus in cancer 
research until now has been on the roles of intragenic mutations and loss of chromosomal 
material (LOH). Hypermethylation should therefore be considered one of the pathways to 
cancer development, and this abnormal methylation is increasingly being recognized as 
an important molecular pathway to satisfy Knudson’s hypothesis. Mechanisms 
responsible for the abnormal methylation of tumor suppressor genes in human cancer are 
not understood.  
                        
However, methylation changes can be present in the apparently normal 
epithelium of certain tissues in a process associated with aging. Jean- Pierre Issa and 
colleagues have found widespread de novo methylation of normally unmethylated CpG 
islands in the colonic epithelium of older patients. While it is not clear what causes CpG 
islands to become de novo methylated, it is probable that the DNA methyltransferase 
enzymes described earlier play an important role in this process. However, it remains to 
be seen whether the changes are due to abnormalities in the regulation of these enzymes 
or are due to changes in chromatin structure that predisposes CpG islands to become 
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abnormally methylated during the process of cell transformation. While the mechanisms 
for abnormal promoter methylation remain to be unravelled, the process of biological 
selection probably plays an important role in the final pattern of methylation observed in 
a given cancer tissue. 
 
Thus, the gradual silencing of growth regulatory genes by ever-increasing 
methylation may result in the selection of cells with enhanced growth potential within the 
tumor. The actual pattern of growth regulators silenced in this way will most likely be a 
reflection of their relative importance in the control of growth in a particular 
differentiated cell type. Evidence for this has come from studies comparing leukaemia 
cells to solid tumors where the pattern of genes inactivated by promoter 
hypermethylation varies, suggesting that the scenario just described may be correct. 
(Peter, 2002). 
1.5 ABOUT GENE 
1.5.1. DNA (cytosine-5)-methyltransferase 3A is an enzyme that in humans is encoded 
by the DNMT3A gene. An epigenetic modification that is CpG methylation is important 
for embryonic development, imprinting, and X-chromosome inactivation. Studies in mice 
have demonstrated that DNA methylation is required for mammalian development. This 
gene encodes a DNA methyltransferase that do function in de novo methylation, rather 
than the maintenance of existing methylated sites. The protein localizes to the cytoplasm 
and nucleus and its expression is developmentally regulated. Alternative splicing results 
in multiple transcript variants encoding different isoforms.  
Function: Required for genome wide de novo methylation and it is essential for the 
establishment of DNA methylation patterns during development. Methylation of DNA is 
coordinated with methylation of histones. It modifies DNA in a non-processive manner 
and also methylates non-CpG sites. May preferentially methylate DNA linker between 2 
nucleosomal cores and is inhibited by histone H1. Plays a role in paternal and maternal 
imprinting. Required for methylation of most imprinted loci in germ cells.  
It acts as a transcriptional co-repressor for ZNF238.Can actively repress 
transcription through the recruitment of HDAC activity.DNA methyltransferase (DNMT) 
add methyl groups to DNA to effect gene expression. There are three types of DNMTs. 
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DNMT1 is predominately responsible for hemi-methylated CpG island methylation, 
DNMT2 in fact transfers methyl groups to RNA not DNA. Hence, has been renamed to t-
RNA aspartic acid methyltransferase 1 (TRDMT1) and DNMT3 is responsible for 
unmethylated CpG island methylation. 
1.5.2. DNA (cytosine-5)-methyltransferase 3 beta, also known as DNMT3B, is a 
protein associated with immunodeficiency, centromere instability and facial anomalies 
syndrome. CpGs methylation is an epigenetic modification that is important for 
embryonic development, imprinting, and X-chromosome inactivation. DNMT3B gene 
encodes a DNA methyltransferase which is thought to function in de novo methylation, 
rather than maintenance methylation. The protein localizes primarily to the nucleus and 
its expression is developmentally regulated. Six alternatively spliced transcript variants 
have been described. CpG methylation is an epigenetic modification that is important for 
embryonic development, imprinting, and X-chromosome inactivation. Mutations in this 
gene cause the immunodeficiency-centromeric instability-facial anomalies (ICF) 
syndrome. Six alternatively spliced transcript variants have been described.  
Function: Required for genome wide de novo methylation and is essential for the 
establishment of DNA methylation patterns during development. DNA methylation is 
coordinated with methylation of histones. May preferentially methylates nucleosomal 
DNA within the nucleosome core region. May function as transcriptional co-repressor by 
associating with CBX4 and independently of DNA methylation. Seems to be involved in 
gene silencing (By similarity).  In association with DNMT1 & and via the recruitment   
of CTCFL/BORIS, involved in activation of BAG1 gene expression by modulating 
demethylation of promoter histone H3 at H3K4 and H3K9. Isoforms 4 and 5 are 
probably not functional due to the deletion of two conserved methyltransferase motifs. 
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1.6 ROLE OF DNMT3A AND DNMT3B IN SOMATIC CELL
 
 
Figure 5-Nucleosomes Containing Methylated DNA Stabilize DNA Methyltransferases 
3A/3B and Ensure Faithful Epigenetic Inheritance (Sharma et al., 2011). 
 
In somatic cells, DNMT3A and DNMT3B remain bound to nucleosomes containing 
methylated DNA, enabling proper maintenance of methylated states in co-operation with 
DNMT1, the maintenance enzyme, which copies the methylation pattern during 
replication by associating with the proliferating cell nuclear antigen (PCNA).  
 
When DNA methylation is lowered by genetic disruption of DNMT1 and DNMT3B in 
DKO cells, DNMT3A loses its ability to bind to nucleosomes which results in 
destabilization and subsequent degradation of the protein. 
 
Restoration of DNA methylation in such hypomethylated cells, through expression of 
exogenous DNMT3B WT or mut) or DNMT3L, increases DNMT3A protein levels by 
enabling it to bind to nucleosomes again which results in stabilization of DNMT(C) 
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Restoration of DNA methylation in such hypomethylated cells, through expression of 
exogenous DNMT3B (WT or mut) or DNMT3L, increases DNMT3A protein levels by 
enabling it to bind to nucleosomes again which results in stabilization of DNMT3A 
protein. Exogenous DNMT3B (WT or mut) also binds strongly to nucleosomes in the 
presence of DNA methylation and synergistically increases methylation along with 
DNMT3A while the excess free DNMT3B protein, which could not anchor to the 
nucleosomes, gets degraded by proteosomal machinery. 
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2. REVIEW OF LITERATURE 
2.1 Hepatocellular Carcinoma can be prevented by Inhibition of denovo-    
methyltransferase 3B 
 For tumor treatment epigenetic therapeutic is a new and rapidly developing area because 
inhibitors of DNA methyltransferase (DNMT) can reverse its changes. Tumorigenesis 
can be occurring by transcriptional silencing of tumor-suppressor genes by CpG 
methylation. Drug-induced Reactivation of methylation silenced tumour suppressor 
genes is the potential way. 5-Aza-2’-deoxycytidine (5-Aza-CdR) inhibits DNA 
methylation and it is used in vitro to induce the re-expression of genes putatively silenced 
by promoter methylation. 
 Aberrant DNA hypermethylation, a prevalent alteration in tumors play important role in 
human cancer, involves in involved in global hypomethylation and specific and gene 
hypermethylation and loss of imprinting. For anti-tumor therapy DNMTs serve as a 
reasonable target. Preclinical work, the growth of cancer cell lines have reversed due to 
DNMT inhibitors and antineoplastic effects has been demonstrated  in animal models, 
includes prolongation of survival. 
 One drug named, 5-aza-2’-deoxycytidine is a potent inhibitor of genomic and promoter 
specific DNA methylation. Limitations of epigenetic therapeutic agents for prevention of 
Tumorigenesis are due to lack of specificity, results in accelerated tumor progression and 
drug toxicity. 
 DNMT1 and DNMT3B both maintain DNA methylation and gene silencing in human 
cancer cells. DNMT3B may not only silence genes by several mechanisms including 
direct DNA methylation or recruitment of proteins that for chromatin modification, but 
also play an important role in transformation. 
 Many induced genes are there for suppression of DNMTs are like   DNMT1 siRNA, 
DNMT3B siRNA and demethylation drug. DNMT3B siRNA induced more tumor-
related genes identical to that of demethylation drug 5-aza-2’-deoxycytidine compared 
with DNMT1. DNMT3B siRNA could induce more genes to demethylation agent in 
Hepatocellular cancer which will be identical (Fana et al., 2008). 
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     2.2 DNA methylation in breast cancer                                                                                                      
 Breast cancer is resulted to be in part from the multiple genetic alterations accumulation 
leading to over expression of oncogene and loss of tumor suppressor. Epigenetic change 
plays a important role as a distinct and mechanism which is very crucial to silence a 
variety of methylated tissue-specific and imprinted genes has emerged in many cancer 
types. 
2.2.1 Altered CpG island methylation, chromatin organization and transcriptional    
regulation. 
 Possible mechanism of transcriptional repression is the interference directly by the 
methylation with the sequence-specific transcription factors binds to it, such as AP-2, 
E2F and NFκB to DNA (Hermann & Doerfler, 1991). 
 Second possibility is methylated CpG sequences recruits transcriptional co repressor like 
mSin3A, DMAP1, TSG101 or Mi2 contributes to transcriptional repression. 
     Methylation of steroid receptor genes in breast cancer. 
 
 The methylation of three members of the steroid hormone super family has been studied 
in breast cancer models. These include estrogen receptor, progesterone receptor and 
retinoic acid receptor. 
 Loss of expression and function of E-cadherin protein contribute increase proliferation, 
invasion and metastasis in breast cancer (Oka et al., 1992). 
 TIMP-3 belongs to a family of molecules that inhibit the proteolytic activity of the 
MMPs (Gomez et al., 1999). This protein suppresses primary tumor growth via its effects 
on tumor development, angiogenesis, invasion and metastasis (Uria et al., 1994). 
 DNMT and HDAC inhibitors are used to treat breast cancer are:- 
i. Classic DNMT inhibitors is 5-Aza-2’-deoxycytidine    
ii. HDAC inhibitors have been identified is Phenyl butyrate 
 
 The importance of epigenetic mechanisms in the transcriptional regulation of critical 
tumor suppressor and growth regulatory genes in breast cancer. These genes include 
those that play crucial roles in DNA repair, cell cycle regulation, cell growth and cell–
cell adhesion. Changes with the intrinsic ability of 5meC to function as a mutagen and 
the negative effects of dysregulated DNMT1 activity, can all contribute to breast cancer 
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Tumorigenesis. Gene expression in a gene-specific and tissue-specific fashion will help 
efforts to modulate gene expression selectively to breast cancer prevention and therapy 
(Yang et.al., 2001) 
        2.3 DNMT3B polymorphisms and risk of primary lung cancer 
 DNA-methyltransferase-3B plays an important role in the generation of aberrant 
methylation in carcinogenesis. Polymorphisms and haplotypes of the DNMT3B gene 
may influence DNMT3B activity on DNA methylation, thereby modulating the 
susceptibility to lung cancer. 
 The DNMT3B gene has two transcriptional start sites, which exist in different exons 
(exon 1Aand1B) and the expression is regulated by different promoters. One promoter is 
nested within a CpG-rich area, whereas the other promoter is found in CpG poor. 
 The DNMT3B −283T > C (–283 bp from exon 1A transcription start site) and −579G > T 
(−579 bp from exon 1B transcription site) polymorphisms are located in the CpG-rich 
and CpG-poor promoters, respectively. 
          Found that these two polymorphisms are in linkage disequilibrium. 
 In the present study, carriers with −283T and −579G alleles were at decreased risk of 
lung cancer as compared with individuals having −283C and −579T alleles. 
 To determine whether the association between the DNMT3B −283T > C and −579G > T 
polymorphisms, and the risk of lung cancer is due to difference in the transcriptional 
activity of the DNMT promoter, we compared the promoter activity of the wild-type 
allele or polymorphic allele of these two polymorphisms by luciferase assay. 
 Since the −283T > C and −579G > T polymorphisms were in LD, the functional effects 
of both polymorphisms might be haplotype-dependent. Therefore, it is reasonable to 
compare the promoter activity of haplotypes (haplotype −283T/−579G versus haplotype 
−283C/−579T). 
 We found that the −283T > C and −579G > T polymorphisms in the DNMT3B promoter, 
and their haplotypes were significantly associated with the risk of lung cancer, 
particularly AC. 
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DNMT3B sequence variants and their biologic function are also needed to understand the 
role of DNMT3B polymorphisms in determining the risk of lung cancer. 
 Genetic polymorphisms often vary between ethnic groups; further studies are needed to 
clarify the association of the DNMT3B polymorphism with lung cancer in diverse ethnic 
populations (Lee, et al., volume 26).  
2.4The Role of DNMT3B in the DNA Methylation of Cancer Cells 
 Cancer cells are characterized by abnormal DNA methylation: Repetitive DNA 
sequences and some gene promoters are hypomethylated and transcriptionally active.  
 Many tumor suppressor gene promoters are hypermethylated and transcriptionally 
inactive without the presence of mutations. 
 Cancer cells exhibit aberrant splicing of the DNMT3B gene, which encodes one of the 
three DNA methyltransferases.  
 The aberrant splicing produces DNMT3B transcripts containing premature stop codons 
and encoding truncated proteins lacking the catalytic domain.  
 Tissue culture cells expressing DNMT3B7, the most frequently observed aberrant 
DNMT3B transcript in cancer cells, show DNA methylation changes that correlate with 
altered gene expression. 
 Transgenic mice that express DNMT3B7 display disrupted embryonic development and 
changes in DNA methylation that are dependent on DNMT3B7 transgene levels. 
 DNMT3B proteins influence DNA methylation in cancer cells and DNA methylation to 
control gene expression. 
        Three Specific Aims: 
I. To examine the effect of DNMT3B7 on mouse. 
II. To study the effect of DNMT3B7 expression on the DNA methylation 
patterns and phenotypes of cancer cells. 
III. To determine how DNMT3B7 could alter DNA methylation 
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 PUBLIC HEALTH RELEVANCE:  
 The DNA within a cell can be modified by methylation to alter its structure and affect 
gene expression. DNA methylation is involved in many normal cellular processes and is 
abnormally distributed in cancer cells, leading to some of the phenotypes of cancer cells.  
 The cancer cells express shortened forms of DNMT3B, one of the enzymes that carry out 
the DNA methylation reaction, and we hypothesize that truncated DNMT3B proteins 
contribute to abnormal DNA methylation patterns in cancer cells. 
 The cellular pathways found to mediate effects of truncated DNMT3B proteins are to 
reveal paradigms common to other processes involves DNA methylation, such as 
mammalian embryonic development, X-chromosome inactivation, genomic imprinting, 
and aging.  ( Lucy A Godley: University of Chicago Country: USA LABOME.ORG) 
 
2.5  DNMT3B gene expression in Human biliary tract carcinoma cell due to 
effect of antisense DNMT3B gene eukaryotic expression plasmid  
 Hypermethylation of the promoter region is major mechanisms of tumor suppressor gene 
inactivation.DNA methyltransferase3B an enzyme that participates in establishment of de 
novo methylation patterns; it is associated closely with hypermethylation of the promoter 
of tumor suppressor genes. 
 DNMT3a and DNMT3B takes part in establishment of de novo methylation.DNMT3a is 
over expressed in various tumors, plays role in Tumorigenesis. 
 The effect of DNA methylation inhibitor 5-aza-2-deoxycytidine is on the cell cycle and 
apoptosis. 
 DNMTs have an important role in Tumorigenesis and development of biliary tract 
carcinoma. Significance is in the regulation of the promoter methylation state and the 
expression of tumor suppressor genes. 
 Antisense technology plays an important role in inhibiting the expression of some 
detrimental genes. 
 Inserted fragment was located at the downstream of the promoters such as SP6, T7 etc. 
 New strand is formed by transcription and this can combine with the endogenous m RNA 
of target gene that compliments with endogenous m RNA and inhibits its splicing and 
maturing. 
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 Expression of m RNA and protein of the target gene can be reduced by antisense 
technology. 
 Construction of the antisense DNMT3B gene eukaryotic expression plasmid by using 
Liposome and transfected into the human biliary tract carcinoma cell line QBC-939. 
 Transfection cell lines were obtained after G418selection. 
 Semi-quantitative RT-PCR was used to observe the effect of transfection with pcDNA-
DNMT3B reduced the expression level of DNMT3B reduced the expression level of 
DNMT3B gene m RNA IN qbc-939. 
 FCM is used to detect the change of expression og DNMT3B protein. 
 Found that transfection with pcDNA-DNMT3B reduced the expression level of the 
DNMT3B protein in QBD-939 (Zuo, et al., 2006).  
    2.6 DNMT potential and its Epigenetic Regulation for Lung Cancer 
 Tumor development is the epigenetic alterations; it is the change of DNA methylation 
patterns, which induce the tumor suppressor gene silence. 
 In one scenario, DNA methyltransferase (DNMT) that is responsible for DNA 
methylation accounts for the major epigenetic maintenance and alternation. 
 In another scenario, DNMT itself is regulated by the environment carcinogens (smoke) 
epigenetic and genetic information. 
 DNMT not only plays a pivotal role in lung Tumorigenesis, but also is a promising 
molecular bio-marker for early lung cancer diagnosis and therapy. 
 DNMT1 and DNMT3B, localized in the nucleolus, could synergistically maintain the 
methylation profile of the human rDNA promoter and regulate its expression. 
 DNMT3B represses the rDNA promoter activity by a methylation independent 
mechanism, different from DNMT1. 
 The over-expression of DNMTs leads to ribosomal DNA (rDNA) hypermethylation; 
subsequently affect the methylation of ribosomal RNA (rRNA) at 2’-O position. 
 The over-expression of DNMT1 is an early indicator in the development of lung cancer, 
which occurs earlier than the methylation disturbance. 
 The RNA interference- based knockdown experiment in NSCLC cell line A549 has 
given evidence that DNMT1 level correlates with the A549 proliferation ability and 
clone forming ability. 
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 The hypermethylation of TSG is a common thing in lung cancer, and it is generally 
acknowledged that DNMT1 is correlated with hypermethylation in the TSG promoters, 
especially among smoking SCC patients (Suzuki et al., 2004). 
 Epigenetically active drugs currently within clinical trials include histone deacetylase 
inhibitors (HDACi) and DNMT inhibitors (DNMTi) and the most extensively studied are 
DNMTi. 
 Alternations of DNA methylation occur even in the precancerous stage before 
establishment of cancer and determine the clinicopathological characteristics of the 
developing malignancies. 
 The proposals of epigenetic biomarker, epigenetic silencing, methylation profiling, 
histone coding, reflect the investigation on epigenetic regulation in lung tumorigenesis 
(Tang et al., 2009).      
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3. OBJECTIVE 
As mentioned above that DNMT3a, DNMT3B is over expressed in many cancers like prostate, 
breast, liver, and colon etc. Deregulation of these genes in human tumors has direct oncogenic 
effects and results essential for cancer cell proliferation. DNA methylation plays a role in gene 
silencing by loss of tumor suppression.  
DNMTs for the hypermethylation of the promoter of the target genes we have to measure the 
expression level of the particular gene of the enzyme. 
So our objective was to compare the expression level of DNMT3A and DNMT3B in cancer 
tissues and normal tissue. 
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4. MATERIALS AND METHODS 
SAMPLE COLLECTION: 
To achieve our objective, blood was collected from CWS Hospital, Rourkela as normal human 
tissue and cancer tissues (Gall Bladder and Lymph Node) from CMC, Kolkata. 
TOTAL RNA ISOLATION: 
     Chemical Reagents and Buffer:- 
 TRIzol Reagents (Sigma) 
 Choloroform 
 Isopropanol 
 Ethanol (70%) 
 Denaturation Buffer- 50 % deionized formamide, 
                                                      2.2 M formaldehyde 
              MOPS buffer (pH 7.0) 
              6.6 % glycerol 
              0.5 % bromophenol  
 Ethidium Bromide 
 Agarose 
 Protocol:- 
 50-100 mg of frozen tissue was transferred to a 2 ml tube with 1 ml TRIzol. 
 Homogenize for 60 sec in the polytron 
 200 l chloroform was then added and mixed by inverting the tube for 15 sec 
 Incubation was done for 3 min at room temperature 
 Centrifuged at 12.000 g for 15 min 
 The aqueous phase was transferred into a fresh Eppenderof  tube 
 Again 500 l isopropanol was added and centrifugation was done at max. 12.000 g for 10 min in 
             the cold room. 
 The pellet was washed with 500 l 70 % ethanol 
 Centrifuged at max. 7.500 g for 5 min in the cold room 
 The pellet was dried on air for 10 min 
 The pellet was dissolved in 50-100 l DEPC-H2O 
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 Incubate was done for 10 min at 60 C 
 Spectrophotometer reading was taken 
 And analyse the RNA on a MOPS gel:  
                                  -Disolve 1-3 g RNA in 11 l denaturation buffer 
                                 - Add 1 l ethidium bromide (1mg/ml) and denaturate at 65 C for 15 min 
                                - Load a 1 % agarose gel in MOPS buffer plus 5 % formaldehyde 
                           - Run the gel at 40 V for 4 h 
cDNA SYNTHESIS: 
    Chemical Regents and Buffer:- 
 5X First Strand Buffer 
 10mM dNTP Set 
 0.1M DTT 
 Random Primers 
 RNAase OUT Ribonuclease Inhibitor 
 SuperScript II RNAase H- Reverse Transcriptase 
     Protocol:- 
 8µl of total RNA was taken. 
 Then 3 μl Random Primers was added to it 
 1 μl dNTP mix was added. 
 Vortex and then spinning was done. 
 Incubated at 65°C for 5 min. 
 The tube was placed on ice. 
 4 μl of 5X Buffer, 2 μl DTT and 1μl RNAase was added. 
 Vortex and then spinning was done again. 
 Incubated at 42°C for 1 min. 
 1μl SuperScript II RNAase H- Reverse Transcriptase was added . 
 Incubation was done at 42°C for 60 min. 
 Again incubated at 70°C for 15 min. 
 180 μl molecular grade water was added. 
 Then Nano drop 1000 was used to measure concentration by setting sample typesetting to Other  
            Sample and the constant to 33 and stored at -80°C. 
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GENE SPECIFIC PCR: 
 Table1:   Primers     
Gene 
Name 
Sense Primer Antisense Primer Tm 
DNMT3A CACACAGAAGCATATCCAGGAGTG AGTGGACTGGGAAACCAAATACCC 66.7 & 
68.5 
DNMT3B AATGTGAATCCAGCCAGCCAGGAA
AGGC 
ACTGGATTACACTCCAGGAACCGT 77.9 & 
67.6 
β-Actin TCTACAATGAGCTGCGTGTG ATCTCCTTCTGCATCCTGTC 62.7 & 
60.8 
 
   PCR Mixture:- (Total 25µl) 
 0.2 µM dNTP- 0.5µl 
 1.5 mM MgCl2- 1.5µl 
 1x PCR Buffer- 2.5µl 
 Taq Polymearse (5U/µl)- 0.5µl 
  Primers (0.2µM)- 0.5µl & 0.5µl 
 cDNA- 2µl 
 MQ Water- 17µl 
   PCR Condition:- 
                 94
o
C1:00[94
o
 C0:20; 65˚C0:20; 72
o
C 0.30]30; 72
o
C 5:00   for DNMT3A. 
                 94
o
C1:00[94
o
 C0:20; 58˚C0:20; 72
o
C 0.30]30; 72
o
C 5:00   for DNMT3B 
                 94
o
C1:00[94
o
 C0:20; 65˚C0:20; 72
o
C 0.30]30; 72
o
C 5:00   for β-actin  
(Patra et.al, 2002) 
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5. RESULTS  
Table2:  Spectrophotometer results of total RNA from blood tissue. 
Product Conc
n
.
 
(µg/ml) Purity 
260/280 260/230 
Total RNA 570.32 1.34 0.82 
 
 
 
 
 
 
 
                   (a) 
Figure 6. Total RNA in a) in 1% agarose gel b) in denaturation gel 
 Table 3: Spectrophotometer results of gene specific amplification product from blood tissue 
Gene Concn.
 
(µg/ml) Purity 
260/280 260/230 
DNMT3A 286.69 1.79 0.96 
DNMT3B 301.58 1.83 0.89 
β-Actin 401.35 1.93 1.02 
 
 
 
   
          (a) 
                     (b) 
 
[Total RNA in denaturation gel] 
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Figure 7. Gel picture showing Gene specific PCR amplification 
 
4: Spectrophotometer results of total RNA from cancerous tissue. 
Tissue Conc
n
.
 
(µg/ml) Purity 
260/280 260/230 
Gall Bladder Cancer 234.67 1.03 0.65 
Lymph Node Cancer 478.51 1.61 1.02 
 
                                                         
                                                Lane.1: Lymph Node Cancer 
                                                            Lane.2: Gall Bladder Cancer         
 
 
Figure 8: Gel picture showing Total RNA in denaturation gel. 
1          2 
 
     1              2             3              
 
Lane.1- β-Actin 
Lane.2- DNMT3A 
Lane.3-DNMT3B 
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    Table 5: Spectrophotometer results of gene specific amplification product from lymph node. 
 
  
er 
 
 
 
 
 
 
 
                     
        Figure 9: Gel picture showing gene specific PCR amplification in cancer tissue. 
 
 
 
 
 
Gene Conc
n
.
 
(µg/ml) Purity 
260/280 260/230 
DNMT3A 353.78 1.87 1.31 
DNMT3B 326.69 1.69 1.25 
β-actin 395.35 1.73 1.19 
1     2        3       4       5      6     7      8          9         10      11 
Lane.1 & 8- β-actin 
 
Lane.7 & 11- Marker 
Lane.9- DNMT3A 
Lane.10- DNMT3B 
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Figure 10: Graph showing comparative study of expression level in both normal an 
cancer  tissue 
After isolation the total RNA from normal blood and Cancerous tissue, we 
checked their concentration by taking its OD in spectrophotometer, in case of Gall 
Bladder the concentration was found to be very low i.e. 234.67µg/ml, which was very 
low compare to the other samples reading. Because it was took a lot of time to processing 
after collecting the sample and also cDNA was not synthesize from the total RNA by rt-
PCR method due to some unsuitable condition. 
It was observed, after gene specific amplification there amazing results were 
found. These were the concentration of DNMT3A and DNMT3B i.e. 286.69 and 301.58 
respectively in normal blood cells, but in cancerous tissue the concentration were found 
to increase i.e. 312.78 and 353.69 respectively.  
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6. DISCUSSION 
After gene specific amplification it was observed that concentration of DNMT3A 
and DNMT 3B has expressed in lymph node cancer tissue. In many research articles, we 
found that DNMT3B shows more expression in cancer tissue, but in Lymph node cancer 
DNMT3A shows over expression as compared to DNMT3B. So from this we can 
hypothesize that these over expression of DNMT3A leads to hypermethylation of TSG 
(for example, p53), which in turn diminish the expression of p53 and causing the cancer. 
We also know that the expression of EZH2 shows the methylation of the histone 
proteins. When the expression of the DNMT 3A and 3B is more the methylation occurs 
and due to this methylation in DNA and also Histone proteins ,the overall cell 
methylation increases leading to the repressing function of the Tumor Suppressor gene. 
Due to this, there will be an increase in the cell number forming a tumor that leads finally 
to the cancer development. This is the reason why the p53 gene (TSGs) concentration has 
been decreased in the lymph node cancer cell which we used for our work. Hence, we 
can predict that due to the increased expression of Denovo Methyltransferases the 
methylation of tumor suppressor genes promoter increased and thus they may be 
repressed. Hence, the cell undergoes rapid cell divisions that may finally lead to tumor 
formation and cancer development. 
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